HARNESS-1 study evaluates RC220 with osimertinib to address treatment resistance in EGFR-mutant non-small cell lung cancer, with the first patient showing no adverse events after initial dosing.
First Patient Dosed | 26/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy